弥漫性大B细胞淋巴瘤中FDG-PET驱动的巩固治疗策略:一项随机2期研究的最终结果
GELA设计了一项随机2期试验,在aaIPI2-3高危弥漫性大B细胞淋巴瘤患者中比较R-ACVBP与R-CHOP14诱导方案,并根据PET结果分配ASCT或标准免疫化疗巩固。R-ACVBP组PET4阴性率53%、CR率47%,R-CHOP14组分别为41%和39%(CR 95%CI 38%-67% vs 28%-54%,P=.076)。R-CHOP14组PET4阳性率更高(54% vs 41%,P=.08),4年EFS更低(31% vs 43%,P<.01),但PFS和OS相似。ΔSUVmax>70%与更好结局相关(4年PFS 84% vs 35%,4年OS 91% vs 57%,P<.0001)。
要点
- R-ACVBP与R-CHOP14的CR率分别为47%和39%,差异未达统计学显著(P=.076)。
- R-CHOP14组PET4阳性率54% vs R-ACVBP组41%(P=.08),4年EFS 31% vs 43%(P<.01)。
- ΔSUVmaxPET0-4>70%者4年PFS 84% vs 35%,4年OS 91% vs 57%(P<.0001)。
核心结论
- R-ACVBP优于R-CHOP14的假设未被证实,因为IHP标准未能恰当反映疾病控制。
- ΔSUVmax可能有助于更好地筛选需要替代标准免疫化疗(包括ASCT)的患者。
研究设计与样本
- GELA设计的随机2期试验,纳入aaIPI2-aaIPI3的弥漫性大B细胞淋巴瘤患者211例,随机分配至R-ACVBP组(n=109)或R-CHOP14组(n=102)。
- PET在基线、2周期(PET2)和4周期(PET4)诱导后 performed,采用IHP标准中心评估。
- PET2-/PET4-患者分配至标准免疫化疗,PET2+/PET4-患者分配至ASCT,PET4+患者由研究者选择治疗。
- 主要终点为诱导后2007年国际工作组完全缓解(CR)率。
主要发现
- R-ACVBP组PET4阴性率53%、CR率47%;R-CHOP14组分别为41%和39%(CR 95%CI分别为38%-67%和28%-54%;P=.076)。
- R-ACVBP组和R-CHOP14组接受标准免疫化疗巩固者分别为26%和23%,接受ASCT者分别为28%和18%。
- R-CHOP14组PET4阳性率高于R-ACVBP组(54% vs 41%;P=.08),导致更多挽救治疗(37% vs 26%;P=.07)和更低的无事件生存(4年EFS 31% vs 43%;P<.01),但两组无进展生存和总生存相似。
- PET2-/PET4-与PET2+/PET4-患者结局相似。
- ΔSUVmaxPET0-4>70%与更好结局相关(4年PFS 84% vs 35%;4年OS 91% vs 57%;P<.0001),无论巩固方式如何。
关键数值与推荐
- PET4阴性率:R-ACVBP组53% vs R-CHOP14组41%。
- CR率:R-ACVBP组47% vs R-CHOP14组39%(95%CI 38%-67% vs 28%-54%;P=.076)。
- PET4阳性率:R-CHOP14组54% vs R-ACVBP组41%(P=.08)。
- 4年EFS:R-CHOP14组31% vs R-ACVBP组43%(P<.01)。
- ΔSUVmaxPET0-4>70%者4年PFS 84% vs 35%,4年OS 91% vs 57%(P<.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dose-dense induction and up-front consolidation with autologous stem cell transplantation (ASCT) remain controversial issues when treating patients with high-risk diffuse large B-cell lymphoma. GELA designed a randomized phase 2 trial evaluating the efficacy of either rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVBP) or rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP14) induction and a positron emission tomography (PET)-driven ASCT or standard immunochemotherapy (SIC) consolidation in age-adjusted international prognosis index 2 (aaIPI2)-aaIPI3 patients. PET was performed at baseline, after 2 (PET2) and 4 (PET4) induction cycles, and centrally assessed using international harmonization project (IHP) criteria. PET2-/PET4- patients were assigned SIC, PET2+/PET4- patients were assigned ASCT, and PET4+ patients were treated with the investigator's choice. The primary end-point was the 2007 international working group complete response (CR) rate after induction. Change in maximum standard uptake value (ΔSUVmax) after PET assessment was explored. Two hundred eleven patients were randomly assigned to R-ACVBP (n = 109) or R-CHOP14 (n = 102). PET4-/CR rates were 53%/47% with R-ACVBP and 41%/39% with R-CHOP14 (CR 95% confidence interval [CI], 38%-67% and 28%-54%, respectively; P = .076). Consolidation in the R-ACVBP and R-CHOP14 groups was SIC in 26% and 23% of patients and ASCT in 28% and 18% of patients, respectively. PET4 positivity was higher with R-CHOP14 vs R-ACVBP (54% vs 41%; P = .08), leading to more salvage therapy (37% vs 26%; P = .07) and lower event-free survival (EFS; 4-year EFS, 31% vs 43%; P < .01), but progression-free survival (PFS) and overall survival (OS) were similar in both groups. PET2-/PET4- and PET2+/PET4- patients had similar outcomes. Using ΔSUVmax, 79% of the patients were PET2-/PET4- ΔSUVmaxPET0-4 >70% was associated with better outcome (4-year PFS, 84% vs 35%; 4-year OS, 91% vs 57%; P < .0001), whatever the consolidation. Superiority of R-ACVBP over R-CHOP14 was not established, as IHP criteria did not properly reflect disease control. ΔSUVmax may help better select patients needing an alternative to SIC, including ASCT.
引用
- Casasnovas RO, Ysebaert L, Thieblemont C, et al. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017. PMID: 28701367. doi:10.1182/blood-2017-02-766691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。